Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Relative risk reduction

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44336   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    106 result(s) found for: Relative risk reduction. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2015-005211-32 Sponsor Protocol Number: DS1040-B-U107 Start Date*: 2017-03-08
    Sponsor Name:Daiichi Sankyo, Inc.
    Full Title: A Phase 1b, Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Single Ascending Dose Study to Assess the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of DS-1040b when Added to ...
    Medical condition: DS-1040b is an inhibitor of the activated form of thrombin-activatable fibrinolysis inhibitor (TAFIa) intended to be used for the treatment of thrombotic diseases including Pulmonary Embolism (PE)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004866 10037379 Pulmonary embolism and thrombosis HLT
    20.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-000591-34 Sponsor Protocol Number: 123456 Start Date*: 2011-05-06
    Sponsor Name:Mater University Hospital
    Full Title: SIRS Steroids In caRdiac Surgery Trial
    Medical condition: Study Objective(s) To determine whether high-risk patients undergoing cardiac surgery requiring CPB derive benefit from perioperative steroids. Study Design Multicentre, International, random...
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2022-000790-94 Sponsor Protocol Number: NN9536-4999 Start Date*: 2022-11-07
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity.
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) PT (Completed) NO (Completed) SK (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-005075-91 Sponsor Protocol Number: STRATIFY-1 Start Date*: 2018-08-30
    Sponsor Name:Copenhagen University Hospital Rigshospitalet
    Full Title: LOW DOSE THROMBOLYSIS, ULTRASOUND ASSISTED THROMBOLYSIS OR HEPARIN FOR INTERMEDIATE HIGH RISK PULMONARY EMBOLISM
    Medical condition: Acute Pulmonary Embolism, intermediate high risk (visible impact on right ventricular structure and function, and biochemical markers og myocardial damage according to the European Society of Cardi...
    Disease: Version SOC Term Classification Code Term Level
    21.0 10038738 - Respiratory, thoracic and mediastinal disorders 10037377 Pulmonary embolism PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-005004-13 Sponsor Protocol Number: NEURAPRO-E FINAL Protocol Start Date*: 2010-10-14
    Sponsor Name:Orygen Research Centre
    Full Title: Add-on Therapie mit Omega-3 Fettsäuren bei Jugendlichen mit hohem Risiko für Schizophrenie und andere psychotische Störungen: eine Multizentren- Replikationsstudie Omega-3 Fatty Acids for Symptomat...
    Medical condition: In view of recent data and after a careful review of potentially neuroprotective treatment options in early psychotic illness, we have decided to replicate the findings of a randomized controlled t...
    Disease:
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-008354-23 Sponsor Protocol Number: ECAL-CCPB-08-07 Start Date*: 2009-04-30
    Sponsor Name:Cubist Pharmaceuticals,INC
    Full Title: CONSERVTM – 2 (Clinical Outcomes and Safety Trial to Investigate Ecallantide’s Effect on Reducing Surgical Blood Loss Volume) – A Phase 2 Randomized Double-Blind Active-Controlled Study in Subjects...
    Medical condition: Reduction of blood loss in subjects exposed to CPB during cardiac surgery at high risk for bleeding
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-002168-17 Sponsor Protocol Number: BAY94-8862/16275 Start Date*: 2015-12-09
    Sponsor Name:Bayer HealthCare AG
    Full Title: A multicenter, randomized, double-blind, double-dummy, parallel-group, active-controlled study to evaluate the efficacy and safety of finerenone compared to eplerenone on morbidity and mortality in...
    Medical condition: Subjects with chronic heart failure and reduced ejection fraction after recent heart failure decompensation and additional risk factors, either type 2 diabetes mellitus or chronic kidney disease or...
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004857 10076410 Chronic kidney disease stage 3 LLT
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    20.0 100000004849 10066498 Cardiac failure chronic aggravated LLT
    21.0 100000004857 10076408 Chronic kidney disease stage 1 LLT
    21.0 100000004857 10076409 Chronic kidney disease stage 2 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended) DK (Prematurely Ended) IE (Prematurely Ended) CZ (Prematurely Ended) DE (Prematurely Ended) FI (Prematurely Ended) GB (Prematurely Ended) AT (Prematurely Ended) HU (Prematurely Ended) NL (Prematurely Ended) PT (Prematurely Ended) ES (Prematurely Ended) LT (Prematurely Ended) BG (Prematurely Ended) PL (Prematurely Ended) GR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004966-17 Sponsor Protocol Number: H8D-MC-EMBH Start Date*: 2006-08-28
    Sponsor Name:Eli Lilly and Company
    Full Title: PPAR Alpha (LY518674): a Phase 2 Dose-Response Study to Evaluate the Blood Pressure-Lowering Effect in Essential Hypertension
    Medical condition: mild essential hypertension
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2016-003502-13 Sponsor Protocol Number: Ca.So. Start Date*: 2018-01-19
    Sponsor Name:AOU DI BOLOGNA POLICLINICO S.ORSOLA-MALPIGHI
    Full Title: A multicenter, randomized, open-label phase 3 study of two anti-angiogenic strategies in advanced hepatocellular carcinoma patients with cross-over at first-line failure: metronomic Capecitabine/So...
    Medical condition: advanced hepatocellular carcinoma
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10024662 Liver cell carcinoma non-resectable LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2009-016620-32 Sponsor Protocol Number: 1.0 Start Date*: 2012-08-10
    Sponsor Name:Dept. of Neurological Surgery, Medical University of Vienna
    Full Title: Intravenous application of milrinone for the treatment and prophylaxis of SAB induced vasospasm
    Medical condition: SAB-induced vasospasm
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Ongoing)
    Trial results: View results
    EudraCT Number: 2020-000620-18 Sponsor Protocol Number: RC20_0082 Start Date*: 2021-02-19
    Sponsor Name:Nantes University Hospital
    Full Title: Human recombinant interferon gamma-1b for the prevention of hospital-acquired pneumonia in critically ill patients: a double-blind, international phase 2, randomized, placebo-controlled trial - the...
    Medical condition: Patients hospitalized in intensive care units, under mechanical ventilation
    Disease: Version SOC Term Classification Code Term Level
    21.1 10042613 - Surgical and medical procedures 10022519 Intensive care PT
    20.0 100000004862 10076918 Hospital acquired pneumonia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2012-003011-58 Sponsor Protocol Number: CACZ885M2301S2 Start Date*: 2012-12-10
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A randomized, double-blind, placebo-controlled, event-driven trial of quarterly subcutaneous canakinumab in the prevention of recurrent cardiovascular events among stable post-myocardial infarction...
    Medical condition: atherosclerosis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) HU (Completed) IT (Prematurely Ended) SK (Completed)
    Trial results: View results
    EudraCT Number: 2013-000239-28 Sponsor Protocol Number: D1693C00001 Start Date*: 2013-07-15
    Sponsor Name:AstraZeneca AB
    Full Title: DECLARE Dapagliflozin Effect on CardiovascuLAR Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence o...
    Medical condition: Type 2 Diabetes mellitus
    Disease: Version SOC Term Classification Code Term Level
    19.1 10027433 - Metabolism and nutrition disorders 10027433 Metabolism and nutrition disorders SOC
    19.1 10027433 - Metabolism and nutrition disorders 10012613 Diabetes mellitus non-insulin-dependent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) IT (Completed) SE (Completed) SK (Completed) BG (Completed) NL (Completed) ES (Completed) DE (Completed) PL (Completed) HU (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-002162-21 Sponsor Protocol Number: JECF-VITD-2011-01 Start Date*: 2012-04-24
    Sponsor Name:José Esteban Castelao Fernández
    Full Title: A phase II randomized, prospective, multicenter, placebo-controlled clinical trial to evaluate the chemopreventive effect of vitamin D in women at high risk of breast cancer.
    Medical condition: Women at high risk of developing breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2022-002235-60 Sponsor Protocol Number: NN9536-7545 Start Date*: 2023-02-24
    Sponsor Name:Novo Nordisk A/S
    Full Title: Effect and safety of semaglutide 7.2 mg once-weekly in participants with obesity and type 2 diabetes
    Medical condition: Obesity
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10029883 Obesity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) SK (Completed) HU (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003249-15 Sponsor Protocol Number: E-BRO-3 Start Date*: 2005-09-26
    Sponsor Name:BIONORICA AG
    Full Title: Efficacy and tolerability of Bronchipret® Saft for the treatment of acute bronchitis in adults A randomized, double-blind, placebo-controlled, parallel-group, multicenter Phase IV study.
    Medical condition: Acute bronchitis with productive cough i.e. onset of bronchial mucus production with impaired ability to cough up.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2010-022890-33 Sponsor Protocol Number: EQol-MDS Start Date*: 2010-11-23
    Sponsor Name:ASSOCIAZIONE QOL-ONE
    Full Title: Eltrombopag for the treatment of thrombocytopenia due to low- and intermediate risk myelodysplastic syndromes.
    Medical condition: Adult patients with low or intermediate-1 IPSS risk MDS and thrombocytopenia
    Disease: Version SOC Term Classification Code Term Level
    9.1 10035534 HLGT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Trial now transitioned) FR (Ongoing) SI (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002570-30 Sponsor Protocol Number: EFC5505 Start Date*: 2005-12-07
    Sponsor Name:Sanofi-Synthelabo Recherche
    Full Title: A multicenter, randomized double-blind placebo controlled Phase III study of the efficacy of xaliproden in preventing the neurotoxicity of oxaliplatin in first-line treatment of patients with metas...
    Medical condition: Patients with metastatic colorectal cancer treated with oxaliplatin/5-FU/LV; at risk of cumulative peripheral sensory neuropathy (PSN) relative to cumulative dose of oxaliplatin.
    Disease: Version SOC Term Classification Code Term Level
    8 10034620 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) ES (Completed) PT (Prematurely Ended) DE (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005400-15 Sponsor Protocol Number: 20110271 Start Date*: 2012-03-22
    Sponsor Name:Amgen Inc
    Full Title: A Multicenter, Open-label Study to Assess the Long-term Safety, Tolerability, and Efficacy of AMG 145 on LDL-C in Subjects With Severe Familial Hypercholesterolemia
    Medical condition: Familial Hypercholesterolemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000012386 10057100 Homozygous familial hypercholesterolaemia LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GR (Completed) CZ (Completed) GB (Completed) ES (Completed) IT (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2006-001183-24 Sponsor Protocol Number: AC-052-321 Start Date*: 2007-03-06
    Sponsor Name:ACTELION PHARMACEUTICALS LTD
    Full Title: Effects of bosentan on morbidity and mortality in patients with Idiopathic Pulmonary Fibrosis - a multicenter, double-blind, randomized, placebo-controlled, parallel group, event-driven, group sequ...
    Medical condition: Idiopathic Pulmonary Fibrosis (IPF)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10021240 Idiopathic pulmonary fibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed) BE (Completed) IE (Completed) GB (Completed) FR (Completed) DE (Completed) AT (Completed) DK (Completed) CZ (Completed) IT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed May 21 13:05:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA